Yes. Thanks for the question.
I think that's very much the case. There are several barriers for moving new ideas to translation into patients. The clinical trial just costs so much money, so I do think there would be significant advantages if there were some mechanism to fund those clinical trials other than the individual companies funding them themselves, or in our case an individual investigator trying to fund them. Individual investigators might have good ideas, but to do a 10,000-person clinical trial is unrealistic. Some support mechanisms to perform those trials would reduce barriers for sure.